News
GLMD
0.5735
0.00%
0.0000
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 4d ago
Galmed Agrees With Acquisition Target Colospan To Increase The Cash Portion Of Purchase Price By $800K In Lieu Of Issuing $2M In Shares
Benzinga · 5d ago
Galmed announces restructured acquisition terms for Colospan
TipRanks · 5d ago
Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure
TipRanks · 5d ago
Galmed restructures Colospan deal terms, swaps $2 million share payment for earnout and extra cash
PUBT · 5d ago
GALMED PHARMACEUTICALS - INCREASES CASH PAYMENT BY $800K, RESTRUCTURES $2 MLN EARNOUT STARTING Q3 2027
Reuters · 5d ago
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
PR Newswire · 5d ago
Weekly Report: what happened at GLMD last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at GLMD last week (0608-0612)?
Weekly Report · 06/15 09:14
Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data
NASDAQ · 06/12 15:36
Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)
TipRanks · 06/10 16:30
Galmed To Acquire Colospan, Creating GI-Focused Platform; Stock Down
NASDAQ · 06/08 14:27
Galmed to acquire Colospan in $4.5M deal; shares down
Seeking Alpha · 06/08 13:31
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion
TipRanks · 06/08 12:47
Galmed to acquire Colospan in cash and stock deal
TipRanks · 06/08 12:27
Galmed Pharmaceuticals Signs Agreement To Acquire Medical Device Firm Colospan For $2.5M In Cash, $2M Galmed Shares
Benzinga · 06/08 12:12
GALMED PHARMACEUTICALS - PLANS $6 MLN INVESTMENT TO LAUNCH COLOSPAN DEVICE IN EUROPE DURING H2 2026
Reuters · 06/08 12:11
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
PR Newswire · 06/08 12:10
Weekly Report: what happened at GLMD last week (0601-0605)?
Weekly Report · 06/08 09:13
UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In Adults
Benzinga · 06/03 15:30
More
Webull provides a variety of real-time GLMD stock news. You can receive the latest news about Galmed Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About GLMD
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.